research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Anti‐keratin Monoclonal Antibody against Basal Cell Epithelioma Keratin: BKN‐1
BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Objective and Subjective Assessments of the Response of Photobiomodulation Therapy Against Alopecia Areata
Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
research High-dose steroid pulse therapy for the treatment of severe alopecia areata.
High-dose steroid pulse therapy effectively regrows hair in severe multifocal alopecia areata.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation
research Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research Spotlight in Plastic Surgery: October 2022
Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
research Microneedling kombinasi minoksidil 5% dengan steroid sistemik dan topikal pada pasien alopesia areata: laporan kasus
The combination therapy improved severe alopecia areata in a patient after 14 days.
research Finasteride/spironolactone
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Alopecia Areata Associated with Myasthenia Gravis and Thymoma: A Case of Alopecia with Marked Improvement Following Thymectomy and High Level Prednisolone Administration
Thymectomy and high-dose prednisolone improved hair loss in a woman with alopecia areata.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Alopecia Areata Barbae in a Nutshell
Beard alopecia areata causes patchy beard hair loss, often treatable with janus kinase inhibitors.
research Latent transforming growth factor beta-binding protein 1 (LTBP1): roles as a multifunctional extracellular matrix regulator in human disease. From molecular mechanisms to clinical translation prospects
LTBP1 is a key regulator in diseases and a potential target for new treatments.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: A retrospective comparative study
Bicalutamide is more effective and safer than spironolactone for treating female hair loss.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research Autoinmune Alopecia/Alopecia Areata
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
research Health-related quality of life in mild-moderate patchy alopecia areata: Results from the first controlled Phase 2 clinical trial in this population with STS01 (dithranol/ProSilic) and challenges for the future
Hair regrowth improved, but quality of life did not.
research Poster Presentations
Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
research 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Lack of efficacy of apremilast in 9 patients with severe alopecia areata
Apremilast did not work for treating severe alopecia areata.
research Intralesional Methotrexate versus Triamcinolone Acetonide for Localized Alopecia Areata (AA) Treatment
Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.